Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Nimvastid 4.5 mg orodispersible tablets
Medicines register · Ireland

Nimvastid 4.5 mg orodispersible tablets

Authorisation EU/1/09/525/37-41 · KRKA, d.d., Novo mesto

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
KRKA, d.d., Novo mesto (all products →)
Active substance
Rivastigmine hydrogen tartrate
Dosage form
Orodispersible tablet
Route of administration
Oral use
ATC codes
N06DA, N06DA03
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Rivastigmine hydrogen tartrate: supply and approvals

37 authorised products on the HPRA list contain Rivastigmine hydrogen tartrate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 525. The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Rivastigmine hydrogen tartrate in Ireland

36 other products on the HPRA list contain Rivastigmine hydrogen tartrate, from 7 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Exelon 1.5 mg hard capsulesNovartis Europharm LimitedCentralised EU authorisationNot stated
Exelon 2 mg/ml oral solutionNovartis Europharm LimitedCentralised EU authorisationNot stated
Exelon 3.0 mg hard capsulesNovartis Europharm LimitedCentralised EU authorisationNot stated
Exelon 4.5 mg hard capsulesNovartis Europharm LimitedCentralised EU authorisationNot stated
Exelon 6.0 mg hard capsulesNovartis Europharm LimitedCentralised EU authorisationNot stated
Nimvastid 1.5 mg hard capsulesKRKA, d.d., Novo mestoCentralised EU authorisationNot stated
Nimvastid 1.5 mg orodispersible tabletsKRKA, d.d., Novo mestoCentralised EU authorisationNot stated
Nimvastid 3 mg hard capsulesKRKA, d.d., Novo mestoCentralised EU authorisationNot stated
Nimvastid 3 mg orodispersible tabletsKRKA, d.d., Novo mestoCentralised EU authorisationNot stated
Nimvastid 4.5 mg hard capsulesKRKA, d.d., Novo mestoCentralised EU authorisationNot stated
Nimvastid 6 mg hard capsulesKRKA, d.d., Novo mestoCentralised EU authorisationNot stated
Nimvastid 6 mg orodispersible tabletsKRKA, d.d., Novo mestoCentralised EU authorisationNot stated

All 37 products with Rivastigmine hydrogen tartrate →

Other substances in ATC group N06DA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group N06DA with this product:

Donepezil hydrochloride (12) · Rivastigmine (6) · Galantamine (5) · Galantamine hydrobromide (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

KRKA, d.d., Novo mesto holds 362 products on the HPRA list, with 117 different active substances; 189 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.